The Future of Oral Peptides: Breaking the Bioavailability Barrier

The oral route is the most convenient and widely preferred method of drug administration, yet the vast majority of peptide therapeutics require injection. This is not an oversight — it reflects fundamental biological and chemical barriers that the gastrointestinal (GI) tract presents to peptide molecules.

The first barrier is enzymatic degradation. The digestive system is specifically designed to break down proteins and peptides into their constituent amino acids for absorption as nutrients. Pepsin in the stomach, trypsin and chymotrypsin in the small intestine, and numerous brush border peptidases on the intestinal epithelium all efficiently cleave peptide bonds. A peptide entering the stomach faces an environment specifically optimised to destroy it.

The second barrier is acidic pH. Gastric acid maintains a pH of approximately 1.5–3.5, which can denature peptide structures, disrupt disulphide bonds, and accelerate chemical degradation reactions such as deamidation and oxidation. Many peptides lose their biological activity within minutes of exposure to gastric acid.

The third barrier is poor membrane permeability. Even if a peptide survives the enzymatic and acidic assault, it must cross the intestinal epithelium to reach the bloodstream. Peptides are typically hydrophilic, charged, and relatively large (molecular weights of 500–5,000 Da or more), making them poor candidates for passive transcellular absorption. The tight junctions between epithelial cells further restrict paracellular transport.

The combined effect of these barriers means that oral bioavailability for most unmodified peptides is well below 1% — effectively zero from a therapeutic standpoint. Overcoming these barriers has been one of the greatest challenges in pharmaceutical science.

The approval of oral semaglutide (Rybelsus) in 2019 represented a landmark achievement — the first oral GLP-1 receptor agonist to reach the market. Developed by Novo Nordisk, it demonstrated that a therapeutic peptide could be delivered orally at clinically meaningful levels.

The key enabling technology was SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), a small-molecule absorption enhancer co-formulated with semaglutide in each tablet. SNAC works through several complementary mechanisms: it creates a localised alkaline microenvironment around the tablet as it dissolves, protecting semaglutide from acid-mediated degradation. It also transiently increases the permeability of the gastric epithelium, facilitating semaglutide absorption across the stomach lining. Additionally, SNAC may protect semaglutide from pepsin by shielding the peptide within lipophilic SNAC aggregates.

Crucially, oral semaglutide is absorbed primarily from the stomach rather than the small intestine — which is unusual for oral drugs but advantageous because it minimises exposure to the more proteolytically active environment of the small intestine.

However, oral semaglutide has significant limitations. Its oral bioavailability is approximately 0.4–1%, meaning that the vast majority of each dose is destroyed in the GI tract. To achieve therapeutic plasma levels comparable to the 1 mg injectable dose, the oral tablet contains 14 mg of semaglutide — roughly 14 times more peptide per dose. Patients must also take the tablet on an empty stomach with no more than 120 mL of water and wait at least 30 minutes before eating, drinking, or taking other medications. These constraints, while manageable, illustrate that SNAC-based delivery is a pragmatic workaround rather than a complete solution to the oral peptide challenge.

Beyond SNAC, a wide array of permeation-enhancing technologies are being developed to improve oral peptide absorption. These approaches aim to transiently increase the permeability of the GI epithelium without causing lasting damage.

Medium-chain fatty acids such as sodium caprate (C10) have been studied extensively as intestinal permeation enhancers. They work by temporarily opening tight junctions between epithelial cells, allowing paracellular transport of peptide molecules. The GIPET (Gastrointestinal Permeation Enhancement Technology) platform, originally developed by Merrion Pharmaceuticals, uses this approach and has been tested with several peptides in clinical trials.

Bile salt-based enhancers leverage natural components of the digestive system. Bile salts such as sodium deoxycholate and sodium glycocholate can solubilise peptides, protect them from enzymatic degradation, and enhance their interaction with the intestinal membrane. Some formulations combine bile salts with fatty acids for synergistic permeation enhancement.

Ionic liquid formulations represent an emerging approach in which peptides are dissolved in choline-based or imidazolium-based ionic liquids that stabilise the peptide in the GI environment and dramatically enhance transepithelial transport. Research published in recent years has demonstrated that ionic liquid-peptide formulations can achieve oral bioavailability improvements of 10–30-fold compared to unformulated peptides in animal models.

Chitosan and its derivatives are mucoadhesive polymers that can open tight junctions and prolong contact time between the peptide formulation and the intestinal mucosa. Thiolated chitosans (thiomers) form disulphide bonds with cysteine-rich subdomains of the mucus layer, providing extended residence time at the absorption site.

While each of these technologies shows promise, a common challenge is achieving sufficient bioavailability improvement to make oral dosing commercially and therapeutically viable without causing unacceptable local toxicity to the GI epithelium.

Nanoparticle-based delivery systems offer a fundamentally different approach to oral peptide delivery. Rather than enhancing permeation of the free peptide, these systems encapsulate the peptide within a protective carrier that shields it from the GI environment and facilitates uptake.

Enteric-coated nanoparticles are designed to pass through the stomach intact and release their peptide payload in the small intestine, where enzymatic activity is lower and the absorptive surface area is much greater. Common materials include PLGA (poly(lactic-co-glycolic acid)), chitosan-alginate complexes, and solid lipid nanoparticles. These carriers can be engineered to respond to specific pH triggers — remaining stable at gastric pH (1.5–3.5) but dissolving at intestinal pH (6.5–7.5).

Self-emulsifying drug delivery systems (SEDDS) and self-nanoemulsifying drug delivery systems (SNEDDS) use lipid-based formulations that spontaneously form nanoemulsions in the GI tract. These systems can incorporate peptides within lipid droplets that are resistant to enzymatic degradation and can be absorbed via lymphatic transport pathways, partially bypassing first-pass hepatic metabolism.

Polymeric micelles and liposomal formulations have also been explored. These systems create a hydrophilic core surrounded by a protective lipophilic shell (or vice versa), enabling the peptide to traverse the lipid bilayer of intestinal epithelial cells. Some formulations incorporate targeting ligands — molecules that bind to specific receptors on enterocytes, triggering receptor-mediated endocytosis and active transport of the peptide across the epithelium.

A particularly innovative approach involves bioadhesive microdevices — tiny, engineered structures that orient themselves against the intestinal wall and create a concentrated zone of peptide delivery at a specific point on the mucosa. The Rani Therapeutics "RaniPill" system, for example, uses a capsule that, upon reaching the intestine, deploys biodegradable microneedles that inject the peptide directly into the intestinal wall, achieving bioavailability comparable to subcutaneous injection.

Some of the most creative solutions to the oral bioavailability problem involve modifying the peptide itself to make it inherently more resistant to degradation and more permeable across biological barriers.

Cell-penetrating peptides (CPPs) are short peptide sequences (typically 5–30 amino acids) that can cross cell membranes efficiently. When conjugated to a therapeutic peptide, CPPs can act as molecular shuttles, ferrying the payload across the intestinal epithelium. Well-known CPPs include TAT (from HIV-1), penetratin, and polyarginine sequences. Research has demonstrated that CPP-conjugated peptides can achieve significantly higher oral bioavailability than their unconjugated counterparts, though the mechanism of membrane crossing (direct penetration vs endocytosis) remains a subject of active investigation.

Stapled peptides are a structural modification strategy in which a hydrocarbon staple is introduced across one or more turns of an alpha-helical peptide. This staple locks the peptide into its bioactive conformation, dramatically increasing its resistance to proteolytic degradation (by presenting fewer accessible cleavage sites to enzymes) and enhancing its membrane permeability (by increasing lipophilicity and reducing conformational flexibility). Aileron Therapeutics pioneered the clinical development of stapled peptides, with candidates targeting intracellular protein-protein interactions that are normally "undruggable."

Cyclisation is a related approach in which the peptide chain is joined head-to-tail or through side-chain linkages to form a cyclic structure. Cyclic peptides are inherently more stable than their linear counterparts, and nature provides abundant proof of concept — cyclosporine, a cyclic peptide immunosuppressant, has been used orally for decades with reasonable bioavailability. Researchers are now applying cyclisation strategies to a wider range of therapeutic peptides, using computational design to identify cyclisation points that preserve biological activity while enhancing oral stability.

These molecular engineering approaches can be combined with formulation strategies — for example, a stapled, cyclised peptide encapsulated in enteric-coated nanoparticles — to achieve multiple layers of protection against GI degradation.

The commercial potential of oral peptide delivery has attracted significant investment from both pharmaceutical giants and innovative biotechnology companies.

Novo Nordisk continues to lead with oral semaglutide and is developing next-generation oral GLP-1 formulations with improved bioavailability and potentially reduced fasting requirements. Their pipeline includes oral amycretin, a dual amylin/GLP-1 agonist designed for oral administration, which early data suggests may achieve weight loss comparable to injectable tirzepatide.

Rani Therapeutics has developed the RaniPill platform, which delivers peptides via intestinal microneedle injection from an orally ingested capsule. This approach achieves near-injectable bioavailability and has been tested with octreotide (a somatostatin analogue) in clinical trials, with additional peptide payloads in development.

Chiasma (now part of Amryt Pharma) developed Mycapssa, an oral formulation of octreotide using the Transient Permeability Enhancer (TPE) technology. This was one of the first oral peptide products to receive regulatory approval and validated the commercial feasibility of oral peptide delivery.

Enteris BioPharma (now part of SWK Holdings) developed the Peptelligence platform, which uses pH-targeted enteric coatings combined with permeation enhancers specifically optimised for each peptide payload. Their technology has been licensed by multiple pharmaceutical partners for oral formulations of calcitonin, parathyroid hormone, and other peptide therapeutics.

Academic research groups worldwide continue to push boundaries with novel approaches including bacterial minicell delivery systems, plant cell-based oral vaccines (where peptide antigens are expressed in plant cells that provide natural protection through the GI tract), and DNA origami nanostructures that can encapsulate and release peptides at targeted sites.

The transition from injectable to oral peptide delivery is underway, but the pace of change varies significantly across different peptide classes and therapeutic areas.

Near term (2026–2028): Improvements to oral semaglutide are expected, including higher-bioavailability formulations that may reduce the fasting requirements and potentially allow lower doses. Oral amycretin and other next-generation oral incretin agonists from Novo Nordisk and competitors are progressing through clinical trials. Additional speciality oral peptide products using established platforms (SNAC, TPE, Peptelligence) are likely to reach the market.

Medium term (2028–2032): Nanoparticle-based and microneedle capsule platforms are expected to mature, potentially enabling oral delivery of peptides that are currently limited to injection. If the RaniPill and similar technologies demonstrate consistent performance in Phase 3 trials, they could open the door to oral formulations of growth hormone secretagogues, BPC-157 analogues, and other research peptides that currently require subcutaneous injection.

Longer term (2032+): Advances in peptide engineering — including stapled peptides, cyclic peptides, and CPP-conjugated designs — may eventually produce therapeutic peptides that are inherently orally bioavailable by design, eliminating the need for complex formulation technologies altogether. Machine learning and AI-driven molecular design are accelerating this process by predicting which structural modifications will enhance oral stability and permeability.

However, it is important to maintain realistic expectations. Oral delivery will not be achievable for all peptides — some are simply too large, too fragile, or too potent (requiring precise dosing that oral variability cannot accommodate). For many therapeutic peptides, injection or nasal delivery will remain the optimal route for the foreseeable future.

This article is for educational purposes only and does not constitute medical or investment advice. The technologies and companies discussed are presented for informational purposes, and their inclusion does not represent an endorsement. Always consult a qualified healthcare professional for guidance on peptide therapeutics.